Stockreport

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors

Kronos Bio, Inc.  (KRON) 
PDF SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeuti [Read more]